Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models
Lewis H Bender, Franco Abbate, Ian B Walters, Lewis H Bender, Franco Abbate, Ian B Walters
Abstract
The recent development of immune-based therapies has improved the outcome for cancer patients; however, adjuvant therapies remain an important line of treatment for several cancer types. To maximize efficacy, checkpoint inhibitors are often combined with cytotoxic agents. While this approach often leads to increased tumor regression, higher off target toxicity often results in certain patients. This report describes a novel formulation comprising a unique amphiphilic molecule, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO), that non-covalently interacts with payloads to increase drug dispersion and diffusion when dosed intratumorally (IT) into solid tumors. SHAO is co-formulated with cisplatin and vinblastine (referred to as INT230-6). IT dosing of the novel formulation achieved greater tumor growth inhibition and improved survival in in vivo tumor models compared to the same drugs without enhancer given intravenously or IT. INT230-6 treatment increased immune infiltrating cells in injected tumors with 10% to 20% of the animals having complete responses and developing systemic immunity to the cancer. INT230-6 was also shown to be synergistic with programmed cell death protein 1 (PD-1) antibodies at improving survival and increasing complete responses. INT230-6 induced significant tumor necrosis potentially releasing antigens to induce the systemic immune-based anti-cancer attack. This research demonstrates a novel, local treatment approach for cancer that minimizes systemic toxicity while stimulating adaptive immunity.
Keywords: CTLA-4; INT230-6; PD-1; antibody; cell-penetration; checkpoint; cisplatin; cytotoxic; diffusion; dispersion; enhancer; immune activation; intratumoral; vinblastine.
Conflict of interest statement
Ian B. Walters, Franco Abbate and Lewis H. Bender have no conflicts.
Figures
References
- DeVita V.T., Jr., Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–8653. doi: 10.1158/0008-5472.CAN-07-6611.
- Yang J., Li W., Luo L., Jiang M., Zhu C., Qin B., Yin H., Yuan X., Yin X., Zhang J., et al. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance. Biomaterials. 2018;182:145–156. doi: 10.1016/j.biomaterials.2018.08.004.
- Gottesman M.M. Mechanisms of cancer drug resistance. Annu Rev. Med. 2002;53:615–627. doi: 10.1146/annurev.med.53.082901.103929.
- Holback H., Yeo Y. Intratumoral drug delivery with nanoparticulate carriers. Pharm Res. 2011;28:1819–1830. doi: 10.1007/s11095-010-0360-y.
- Palumbo M.O., Kavan P., Miller W.H., Jr., Panasci L., Assouline S., Johnson N., Cohen V., Patenaude F., Pollak M., Jagoe R.T., et al. Systemic cancer therapy: Achievements and challenges that lie ahead. Front Pharmacol. 2013;4:57. doi: 10.3389/fphar.2013.00057.
- Gardner R.V. Long term hematopoietic damage after chemotherapy and cytokine. Front Biosci. 1999;4:e47–e57. doi: 10.2741/A479.
- Galluzzi L., Buque A., Kepp O., Zitvogel L., Kroemer G. Immunological Effects of Conventional Chemotherapy and Targeted Anticancer. Agents. Cancer Cell. 2015;28:690–714.
- Lammers T., Peschke P., Kuhnlein R., Subr V., Ulbrich K., Huber P., Hennink W., Storm G. Effect of intratumoral injection on the biodistribution and the therapeutic potential of HPMA copolymer-based drug delivery systems. Neoplasia. 2006;8:788–795. doi: 10.1593/neo.06436.
- Goldberg E.P., Hadba A.R., Almond B.A., Marotta J.S. Intratumoral cancer chemotherapy and immunotherapy: Opportunities for nonsystemic preoperative drug delivery. J. Pharm. Pharmacol. 2002;54:159–180. doi: 10.1211/0022357021778268.
- Solorio L., Patel R.B., Wu H., Krupka T., Exner A.A. Advances in image-guided intratumoral drug delivery techniques. Ther. Deliv. 2010;1:307–322. doi: 10.4155/tde.10.20.
- Brincker H. Direct intratumoral chemotherapy. Crit Rev. Oncol Hematol. 1993;15:91–98. doi: 10.1016/1040-8428(93)90049-A.
- Walter K.A., Tamargo R.J., Olivi A., Burger P.C., Brem H. Intratumoral chemotherapy. Neurosurgery. 1995;37:1128–1145. doi: 10.1227/00006123-199512000-00013.
- Voulgaris S., Partheni M., Karamouzis M., Dimopoulos P., Papadakis N., Kalofonos H.P. Intratumoral doxorubicin in patients with malignant brain gliomas. Am. J. Clin. Oncol. 2002;25:60–64. doi: 10.1097/00000421-200202000-00013.
- Duvillard C., Romanet P., Cosmidis A., Beaudouin N., Chauffert B. Phase 2 study of intratumoral cisplatin and epinephrine treatment for locally recurrent head and neck tumors. Ann. Otol. Rhinol. Laryngol. 2004;113:229–233. doi: 10.1177/000348940411300312.
- Fakhari A., Anand Subramony J. Engineered in-situ depot-forming hydrogels for intratumoral drug delivery. Pt AJ. Control. Release. 2015;220:465–475. doi: 10.1016/j.jconrel.2015.11.014.
- Zarogoulidis P., Pavlioglou P., Pivert P.L., Machairiotis N., Katsikogiannis N., Kougioumtzi I., Tsimogiannis K., Kakolyris S., Courcoutsakis N., Tsiouda T., et al. Current and future intratumoral targeted treatment for pancreatic cancer. Ther. Deliv. 2014;5:913–926. doi: 10.4155/tde.14.44.
- Weinberg B.D., Blanco E., Gao J. Polymer implants for intratumoral drug delivery and cancer therapy. J. Pharm. Sci. 2008;97:1681–1702. doi: 10.1002/jps.21038.
- Kerr D., McArdle C. Regional Chemotherapy: Theory and Practice. Taylor & Francis; Abingdon, UK: 2000 Harwood Academic Publishers; Amsterdam, The Netherlands:
- Holzer A.K., Manorek G.H., Howell S.B. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol. 2006;70:1390–1394. doi: 10.1124/mol.106.022624.
- Yang N.J., Hinner M.J. Getting across the cell membrane: An overview for small molecules, peptides, and proteins. Methods Mol. Biol. 2015;1266:29–53.
- US Food and Drug Administration FDA Approves First-Of-Its-Kind Product for the Treatment of Melanoma 2015. [(accessed on 22 June 2020)]; updated 27 October 2015. Available online: .
- IMLYGIC . Talimogene Laherparepvec. BioVex, Inc (a subsidiary of Amgen Inc); Thousand Oaks, CA, USA: 2017.
- 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) J. Immunol. Ther. Cancer. 2018;6:115.
- Malkov D., Angelo R., Wang H.Z., Flanders E., Tang H., Gomez-Orellana I. Oral delivery of insulin with the eligen technology: Mechanistic studies. Curr. Drug Deliv. 2005;2:191–197. doi: 10.2174/1567201053586001.
- Majuru S. Advances in the Oral Delivery of Heparin from Solid Dosage Forms Using Emisphere’s eligen® Oral Drug Delivery Technology 2004. [(accessed on 17 January 2020)]; updated 2008, cited 2004. Available online: .
- Leone-Bay A., Ho K.-K., Press J. Emisphere Technologies, Inc, assignee. Compositions for oral delivery of active agents. 5,650,386 A. U.S. Patent. 1997
- Baughman R.A., Kapoor S.C., Agarwal R.K., Kisicki J., Catella-Lawson F., FitzGerald G.A. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation. 1998;98:1610–1615. doi: 10.1161/01.CIR.98.16.1610.
- Ding X., Rath P., Angelo R., Stringfellow T., Flanders E., Dinh S., Gomez-Orellana I., Robinson J.R. Oral absorption enhancement of cromolyn sodium through noncovalent complexation. Pharm. Res. 2004;21:2196–2206. doi: 10.1007/s11095-004-7671-9.
- Komizu Y., Ueoka H., Ueoka R. Selective accumulation and growth inhibition of hybrid liposomes to human hepatocellular carcinoma cells in relation to fluidity of plasma membranes. Biochem. Biophys. Res. Commun. 2012;418:81–86. doi: 10.1016/j.bbrc.2011.12.134.
- Zivec K., Ziherl K. Fluidity of red blood cells membranes in cancer patients—an electronic paramagnetic resonance study. Med. Razgl. 2006;45:3–19.
- Marguet D., Lenne P.F., Rigneault H., He H.T. Dynamics in the plasma membrane: How to combine fluidity and order. EMBO J. 2006;25:3446–3457. doi: 10.1038/sj.emboj.7601204.
- Garg S., Dhavala S., Krumova K., Kiebish M., Vishnudas V., Gesta S., Sarangarajan R., Rarain N. Membrane Fluidity in Cancer Cell Membranes as a Therapeutic Target: Validation using BPM 31510. Biophys. J. 2015;108:246a. doi: 10.1016/j.bpj.2014.11.1361.
- Bloom A.C., Bender L.H., Tiwary S., Pasquet L., Clark K., Jiang T., Xia Z., Morales-Kastresana A., Jones J.C., Walters I., et al. Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. OncoImmunology. 2019 doi: 10.1080/2162402X.2019.1625687.
- Bristol-Myers Squibb Company OPDIVO (nivolumab) prescribing information 2020. [(accessed on 22 June 2020)]; Available online:
- Dasari S., Tchounwou P.B. Cisplatin in cancer therapy: Molecular mechanisms of action. Eur. J. Pharmacol. 2014;740:364–378. doi: 10.1016/j.ejphar.2014.07.025.
- Mehmood R.K. Review of Cisplatin and oxaliplatin in current immunogenic and monoclonal antibody treatments. Oncol Rev. 2014;8:256. doi: 10.4081/oncol.2014.256.
- Tang D., Kang R., Zeh H.J., 3rd, Lotze M.T. High-mobility group box 1 and cancer. Biochim. Biophys. Acta. 2010;1799:131–140. doi: 10.1016/j.bbagrm.2009.11.014.
- Mathios D., Kim J.E., Mangraviti A., Phallen J., Park C.K., Jackson C.M., Garzon-Muvdi T., Kim E., Theodros D., Polanczyk M., et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 2016;8:370ra180. doi: 10.1126/scitranslmed.aag2942.
- Ariyan C.E., Brady M.S., Siegelbaum R.H., Hu J., Bello D.M., Rand J., Fisher C., Lefkowitz R.A., Panageas K.S., Pulitzer M., et al. Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunol. Res. 2018;6:189–200. doi: 10.1158/2326-6066.CIR-17-0356.
Source: PubMed